Arbutus Biopharma Corporation (ABUS) Insider Sells $111,000.00 in Stock
Arbutus Biopharma Corporation (NASDAQ:ABUS) insider Michael J. Sofia sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $3.70, for a total value of $111,000.00. Following the completion of the transaction, the insider now directly owns 1,563,403 shares in the company, valued at $5,784,591.10. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Arbutus Biopharma Corporation (NASDAQ:ABUS) remained flat at $3.60 on Friday. The company had a trading volume of 17,707 shares. The stock’s 50-day moving average price is $3.67 and its 200 day moving average price is $3.30. Arbutus Biopharma Corporation has a 12-month low of $2.35 and a 12-month high of $4.04. The stock’s market capitalization is $198.09 million.
A number of research firms recently commented on ABUS. Zacks Investment Research cut Arbutus Biopharma Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Chardan Capital reissued a “buy” rating on shares of Arbutus Biopharma Corporation in a report on Monday, August 7th. Finally, Ladenburg Thalmann Financial Services began coverage on Arbutus Biopharma Corporation in a report on Friday, June 2nd. They issued a “buy” rating and a $32.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Arbutus Biopharma Corporation has an average rating of “Buy” and a consensus price target of $11.65.
A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Arbutus Biopharma Corporation by 2.7% in the second quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock worth $279,000 after buying an additional 2,035 shares in the last quarter. OxFORD Asset Management LLP increased its position in Arbutus Biopharma Corporation by 89.9% in the second quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 39,436 shares during the period. Renaissance Technologies LLC increased its position in Arbutus Biopharma Corporation by 785.1% in the first quarter. Renaissance Technologies LLC now owns 124,573 shares of the biopharmaceutical company’s stock valued at $405,000 after buying an additional 110,499 shares during the period. Victory Capital Management Inc. purchased a new position in Arbutus Biopharma Corporation during the second quarter valued at $478,000. Finally, Bank of Montreal Can increased its position in Arbutus Biopharma Corporation by 1.9% in the second quarter. Bank of Montreal Can now owns 874,254 shares of the biopharmaceutical company’s stock valued at $3,147,000 after buying an additional 16,535 shares during the period. Institutional investors own 66.49% of the company’s stock.
Arbutus Biopharma Corporation Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Stock Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related stocks with our FREE daily email newsletter.